Illumina Advances Precision Oncology And Gains Speed In Infectious Disease
Greater Use Of Genomics For Surveillance During COVID-19 Has Shown That Scientists Will No Longer Fight Blind In Infectious Disease Control
Executive Summary
Illumina’s moves into infectious disease testing and further into the clinical setting have been accelerated by the pandemic. The genomic sequencing company is also fast expanding its companion diagnostics oncology partnerships.